Workflow
北陆药业(300016.SZ):海昌药业碘美普尔化学原料药获批上市

Core Viewpoint - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Iopamidol, a contrast agent used in medical imaging [1] Group 1: Company Developments - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has been granted a marketing approval for Iopamidol, which is a raw material for the contrast agent Iopamidol injection [1] - Iopamidol is characterized as a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and vascular imaging [1]